Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

2.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

3.

Multiplexed analysis of fixed tissue RNA using Ligation in situ Hybridization.

Credle JJ, Itoh CY, Yuan T, Sharma R, Scott ER, Workman RE, Fan Y, Housseau F, Llosa NJ, Bell WR, Miller H, Zhang SX, Timp W, Larman HB.

Nucleic Acids Res. 2017 Aug 21;45(14):e128. doi: 10.1093/nar/gkx471.

4.

Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Llosa NJ, Cooke KR, Chen AR, Gamper CJ, Klein OR, Zambidis ET, Luber B, Rosner G, Siegel N, Holuba MJ, Robey N, Hayashi M, Jones RJ, Fuchs E, Holdhoff M, Loeb DM, Symons HJ.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2127-2136. doi: 10.1016/j.bbmt.2017.08.012. Epub 2017 Aug 12.

5.

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Klein OR, Buddenbaum J, Tucker N, Chen AR, Gamper CJ, Loeb D, Zambidis E, Llosa NJ, Huo JS, Robey N, Holuba MJ, Kasamon YL, McCurdy SR, Ambinder R, Bolaños-Meade J, Luznik L, Fuchs EJ, Jones RJ, Cooke KR, Symons HJ.

Biol Blood Marrow Transplant. 2017 Feb;23(2):325-332. doi: 10.1016/j.bbmt.2016.11.016. Epub 2016 Nov 22.

6.

Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report.

Shad AT, Huo JS, Darcy C, Abu-Ghosh A, Esposito G, Holuba MJ, Robey N, Cooke KR, Symons HJ, Chen AR, Llosa NJ.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26257. Epub 2016 Sep 21.

PMID:
27650634
7.

Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.

Hayashi M, Chu D, Meyer CF, Llosa NJ, McCarty G, Morris CD, Levin AS, Wolinsky JP, Albert CM, Steppan DA, Park BH, Loeb DM.

Cancer. 2016 Oct;122(19):3015-23. doi: 10.1002/cncr.30144. Epub 2016 Jun 28.

8.

Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis.

Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, Smith KN, Tam A, Ganguly S, Wanyiri JW, Iyadorai T, Malik AA, Roslani AC, Vadivelu JS, Van Meerbeke S, Huso DL, Pardoll DM, Sears CL.

Cancer Res. 2016 Apr 15;76(8):2115-24. doi: 10.1158/0008-5472.CAN-15-0749. Epub 2016 Feb 15.

9.

Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.

Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, Huo J, Cooke KR, Jones R, Fuchs E, Luznik L, Symons HJ.

Biol Blood Marrow Transplant. 2016 Jan;22(1):112-8. doi: 10.1016/j.bbmt.2015.08.034. Epub 2015 Sep 4.

10.

Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic.

Housseau F, Llosa NJ.

Oncoimmunology. 2015 Mar 19;4(6):e1008858. eCollection 2015 Jun.

11.

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F.

Cancer Discov. 2015 Jan;5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863. Epub 2014 Oct 30.

12.

Interleukin-17 and type 17 helper T cells in cancer management and research.

Llosa NJ, Geis AL, Thiele Orberg E, Housseau F.

Immunotargets Ther. 2014 Mar 10;3:39-54. doi: 10.2147/ITT.S56529. eCollection 2014. Review.

13.

Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.

Campodónico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB.

Infect Immun. 2011 Aug;79(8):3455-64. doi: 10.1128/IAI.00157-11. Epub 2011 May 31.

14.

Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.

Campodónico VL, Llosa NJ, Grout M, Döring G, Maira-Litrán T, Pier GB.

Infect Immun. 2010 Feb;78(2):746-55. doi: 10.1128/IAI.00806-09. Epub 2009 Dec 7.

Supplemental Content

Loading ...
Support Center